Table 1 Characteristics of enrolled patients and univariate analysis for PFS and OS
N | First-line progression-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|
Feature | 144 | % | Median (months) | HR (95% CI) | P -value | Median (months) | HR (95% CI) | P -value |
Median age (range) | 64 (23–81) | |||||||
⩽65 years | 76 | 53 | 9.7 | 1.3 (0.9–1.8) | 0.1 | 32.2 | 1.1 (0.8–1.7) | 0.5 |
>65 years | 68 | 47 | 8.1 | 29.3 | ||||
Gender | ||||||||
Male | 82 | 57 | 8.9 | 1.3 (0.9–1.8) | 0.2 | 30.2 | 1.2 (0.8–1.7) | 0.5 |
Female | 62 | 43 | 10.3 | 32.1 | ||||
Stage at diagnosis | ||||||||
I–III | 82 | 57 | 9.4 | 1.1 (0.7–1.7) | 0.9 | 31.3 | 1.4 (0.8–2.3) | 0.2 |
IV | 62 | 43 | 8.1 | 32.1 | ||||
Tumour location | ||||||||
Colon | 105 | 73 | 9.8 | 1.3 (0.6–2.6) | 0.5 | 29.8 | 1.7 (0.7–4.6) | 0.3 |
Rectum | 39 | 27 | 10.4 | 31.9 | ||||
Number of treatment lines | Median: 3 | |||||||
1 | 29.8 | |||||||
2 | 34.8 | 0.8 (0.5–1.5) | 0.6 | |||||
3 | 44.2 | 0.4 (0.2–0.0) | 0.02 | |||||
Histological grade | ||||||||
I–II | 107 | 74 | 12.2 | 2.0 (1.3–3.2) | 0.001 | 39.2 | 2.7 (1.6–4.4) | <0.001 |
III | 37 | 26 | 7.6 | 23.8 | ||||
Adjuvant treatment | ||||||||
Yes | 58 | 40 | 9.5 | 1.2 (0.6–2.5) | 0.5 | 31.6 | 1.1 (0.6–1.8) | 0.9 |
No | 86 | 60 | 10.2 | 31.4 | ||||
Metastasectomy | ||||||||
Yes | 21 | 15 | 24.2 | 0.5 (0.2–0.7) | <0.001 | 48.7 | 0.6 (0.2–0.9) | 0.03 |
No | 123 | 85 | 9.1 | 31.4 | ||||
BRAF status | ||||||||
Mutant | 12 | 8 | 2.7 | 2.9 (1.6–5.4) | <0.001 | 14.0 | 4.3 (2.3–8.2) | <0.001 |
Wt | 132 | 92 | 9.8 | 30.3 | ||||
MSI status | ||||||||
High | 22 | 15 | 9.7 | 1.0 (0.7–1.7) | 0.8 | 21.3 | 1.3 (0.8–2.1) | 0.3 |
Stable | 122 | 85 | 10.4 | 30.2 | ||||
Cyclin D1 | ||||||||
Overexpression | 26 | 18 | 8.3 | 0.8 (0.5–1.4) | 0.1 | 21.7 | 1.1 (0.6–1.8) | 0.7 |
Weak expression | 63 | 44 | 9.1 | 29.1 | ||||
No expression | 55 | 38 | 11.5 | 30.3 | ||||
